Shenqi(SH:600613) Huan Qiu Wang·2025-09-29 10:33Core Viewpoint - The company, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., has received administrative regulatory measures from the Shanghai Securities Regulatory Bureau due to irregularities in its accounting practices, specifically related to the handling of accounts receivable [1][2]. Group 1: Regulatory Actions - The Shanghai Securities Regulatory Bureau has mandated corrective measures for the company and issued warning letters to key executives, including the chairman and general manager, for their lack of diligence [1]. - The company is required to submit a written rectification report within 30 days and is expected to improve its accounting practices to prevent future occurrences [2]. Group 2: Financial Impact - In the first half of 2025, the company reported a revenue of 961 million yuan, a decrease of 13.47% year-on-year, and a net profit attributable to shareholders of 32.81 million yuan, down 13.29% year-on-year [2]. Group 3: Company Background - Shanghai Shenqi Pharmaceutical was listed on August 20, 1992, and its main business includes the research, production, and sales of pharmaceuticals, with key products being sodium cantharidate vitamin B6 injection and sodium cantharidate injection [2].